Variable | OS | DSS | DMFS | LRFS | ||||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
IC regimen (PF vs. TPF) | 0.660 (0.442–0.986) | 0.042 | 0.624 (0.411–0.947) | 0.027 | 0.589 (0.406–0.855) | 0.005 | 1.213 (0.719–2.047) | 0.469 |
Gender (male vs. female) | 0.812 (0.581–1.135) | 0.223 | 0.727 (0.510–1.037) | 0.079 | 0.918 (0.640–1.317) | 0.643 | 0.649 (0.381–1.106) | 0.112 |
Age | 1.027 (1.016–1.039) | 0.001 | 1.024 (1.012–1.036) | 0.001 | 1.013 (1.000–1.025) | 0.044 | 1.020 (1.003–1.037) | 0.023 |
Smoking (yes vs. no) | 1.041 (0.796–1.363) | 0.768 | 1.003 (0.760–1.323) | 0.985 | 0.944 (0.694–1.285) | 0.715 | 0.976 (0.648–1.472) | 0.909 |
T stage (T1–2 vs. T3–4) | 1.393 (1.178–1.648) | 0.001 | 1.231 (0.979–1.549) | 0.075 | 1.306 (1.086–1.570) | 0.005 | 1.420 (1.094–1.842) | 0.008 |
N stage (N0–1 vs. N2–3) | 1.308 (1.135–1.509) | 0.001 | 1.177 (1.028–1.349) | 0.018 | 1.547 (1.312–1.824) | 0.001 | 1.146 (0.902–1.456) | 0.266 |
Clinical stage (III vs. IV) | 1.185 (0.855–1.642) | 0.309 | 1.630 (1.268–2.097) | 0.027 | 1.012 (0.701–1.460) | 0.951 | 0.909 (0.526–1.572) | 0.734 |
CDDP dose (< 200 mg/m2 vs. ≥ 200 mg/m2) | 0.884 (0.695–1.125) | 0.316 | 0.869 (0.676–1.118) | 0.276 | 1.012 (0.772–1.327) | 0.930 | 1.054 (0.728–1.526) | 0.782 |
Number of IC cycles (< 2 cycles vs. ≥ 2 cycles) | 1.089 (0.782–1.518) | 0.613 | 1.121 (0.788–1.593) | 0.526 | 1.217 (0.809–1.829) | 0.346 | 0.899 (0.551–1.467) | 0.670 |
Time to RT (< 60 days vs. ≥ 60 days) | 0.874 (0.650–1.173) | 0.369 | 0.840 (0.618–1.142) | 0.265 | 1.102 (0.807–1.506) | 0.541 | 0.857 (0.548–1.339) | 0.498 |
Radiation technique (IMRT vs. 2D-CRT) | 1.540 (1.134–2.091) | 0.006 | 1.442 (1.053–1.975) | 0.022 | 1.273 (0.914–1.775) | 0.153 | 1.015 (0.654–1.574) | 0.948 |